Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine

Yachun Zhang; Ming Zhou; Yingying Li; Zhaochen Luo; Huanchun Chen; Min Cui; Zhen F. Fu; Ling Zhao

doi:10.18632/oncotarget.23160

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine

Yachun Zhang, Ming Zhou, Yingying Li, Zhaochen Luo, Huanchun Chen, Min Cui, Zhen F. Fu and Ling Zhao _

PDF | HTML | How to cite

Oncotarget. 2018; 9:831-841. https://doi.org/10.18632/oncotarget.23160

Metrics: PDF 1471 views | HTML 2565 views | ?

Abstract

Yachun Zhang1,2, Ming Zhou1,2, Yingying Li1,2, Zhaochen Luo1,2, Huanchun Chen1,2, Min Cui1,2, Zhen F. Fu1,2,3 and Ling Zhao1,2

1State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China

2College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China

3Department of Pathology, University of Georgia, Athens, GA 30602, USA

Correspondence to:

Ling Zhao, email: [email protected]

Keywords: rabies virus; dendritic cells; DC-binding peptides; rabies vaccine

Received: September 14, 2017 Accepted: November 15, 2017 Published: December 11, 2017

ABSTRACT

Our previous studies demonstrated that recruiting and/or activating dendritic cells (DCs) enhanced the immunogenicity of recombinant rabies viruses (rRABV). In this study, rRABV LBNSE with a small DC-binding peptide (designated as rLBNSE-DCBp) or a negative control peptide (designated as rLBNSE-DCCp) fused to the glycoprotein (G) was constructed and rescued. As expected, significantly more activated DCs were detected in rLBNSE-DCBp-immunized mice than those immunized with rLBNSE or rLBNSE-DCCp. Subsequently, significantly more generation of T_FH and GC B cells were observed in rLBNSE-DCBp immunized mice than those in rLBNSE or rLBNSE-DCCp-immunized mice. In addition, significantly higher levels of virus neutralizing antibodies (VNAs) were observed in mice immunized with rLBNSE-DCBp than those immunized with rLBNSE or rLBNSE-DCCp, resulting in a better protection of rLBNSE-DCBp immunized mice against the lethal challenge. Taken together, our results suggest that rRABV with G fused with DCBp is a promising rabies vaccine candidate.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23160

Publication Alerts

Research Papers:

Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine

Abstract